Stocks
Anavex Life Sciences Mails Letter to Stockholders Reinforcing Relevant Experience of All Six Director Nominees
Launches VoteAnavex.com to Provide Additional Information on Anavex’s Director Nominees and How to Vote at the Annual Meeting of Stockholders NEW YORK, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (“CNS”) diseases with high unmet medical needs, today announced that the Executive Committee of the Anavex Board of Directors (th
About this update from Anavex Life Sciences Corp.
Launches VoteAnavex.com to Provide Additional Information on Anavex's Director Nominees and How to Vote at the Annual Meeting of Stockholders NEW YORK, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system ("CNS") diseases with high unmet medical needs, today announced that the Executive Committee of the Anavex Board of Directors (the "Executive Committee") has mailed a letter to stockholders encouraging them to vote the WHITE proxy card "FOR" all six of Anavex's highly qualified directors standing for election at the Company's 2026 Annual Meeting of Stockholders (the "Annual Meeting"). The full text of the letter being mailed to stockholders has been filed with the U.S. Security and Exchange Commission (SEC) and is available at www.VoteAnavex.com along with voting instructions and other information about the Annual Meeting. The letter highlights the following six highly qualified, independent director nominees and the complementary skills and experience each nominee brings: The Annual Meeting will be held on September 24, 2026, and stockholders of record as of close of business on July 31, 2026 are entitled to vote. If you have any questions or require any assistance with voting your shares, please call: Innisfree M&A Incorporated 500 Fifth Avenue, 21st FloorNew York, NY 10110Stockholders may call toll-free at (877) 750-0831Brokers, banks and other nominees may call collect at (212) 750-5833 About Anavex Life Sciences Corp.Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders. Further information is available at www.anavex.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements regarding the Company's plans, strategies and expectations regarding the 2026 Annual Meeting, director nominations, the proxy solicitation, the Company's go-forward strategy, clinical development programs, business prospects, and potential ...
View stock analysis, news, and events for Anavex Life Sciences Corp.